Arthritis Rheumatol: Kanamono resistance and safety in sJIA patients.

The study !---- to assess the long-term efficacy and safety of carnazumast and to explore the predictions of treatment responses to patients with fever-non-fever-non-fever-type systemic juvenile isoarthritis (sJIA).into the group, active sJIA patients (2 to 20 years of age) began to use the open-label karnamonotag (4mg/kg per 4 weeks for subcutaneous injections of q4w).efficacy indicators include improved JIA American Rheumatology Society (aJIA-ACR) standards, juvenile arthritis activity score (JADAS) and clinical inactive diseases (CID)/drug mitigation (CR) assessed by JADAS (CIDJADAS/CRJADAS) or ACR standards (CIDACR/CRACR).in 123 patients (fever, n-70; no fever, n-52), 84 patients (68.3%) completed the study (median time of 1.8 years). On the 15th day of the, considerable efficacy was observed in two subgroups (aJIA-ACR 50/70/90/100) (fever group: 60.0%/48.6%/37.1%/24.3%;to the 6th month, 17 (24.3%) and 26 (37.1%) fever patients were CRJADAS and CRACR, respectively, compared with 9 (17.3%) and 12 (23.1%) without fever.fever/non-fever group reached the median time of CRJADAS/CRACR, 57/30 days and 58/142 days, respectively.aJIA-ACR50 response on the 15th day is the strongest predictor of CRJADAS (OR: 13,4-42, ;p.0001) or glucocorticoid discontinuation (OR: 19 ,3-114) ;p .002).71 patients who received glucocorticoid therapy at the beginning of the study (57.7 percent), 27 (38.0 percent), 21 (29.6 percent) dose s;lt;0.2 mg/kg/day, and no difference between fever and non-fever subgroups.13 patients (10.6%) to the persistent dose of karnamonob continued to decrease to 2 mg/kg/q4w.no new security issues were identified.whether or not there is fever at the beginning of treatment, Kanamonoresistance can lead to rapid and continuous improvement in active sJIA..